Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (103) 103
science & technology (102) 102
life sciences & biomedicine (98) 98
female (87) 87
male (87) 87
middle aged (79) 79
adult (76) 76
hepatitis c, chronic - drug therapy (58) 58
hepacivirus - genetics (53) 53
antiviral agents - therapeutic use (51) 51
gastroenterology & hepatology (51) 51
aged (50) 50
genotype (49) 49
biological and medical sciences (48) 48
infectious diseases (48) 48
medical sciences (48) 48
treatment outcome (48) 48
drug therapy, combination (45) 45
hepatitis c (39) 39
human viral diseases (37) 37
viral diseases (37) 37
interferon-alpha - therapeutic use (34) 34
antiviral agents - adverse effects (33) 33
ribavirin - therapeutic use (33) 33
hepatitis c, chronic - virology (30) 30
polyethylene glycols - therapeutic use (29) 29
viral hepatitis (29) 29
recombinant proteins (28) 28
antiviral agents - administration & dosage (27) 27
gastroenterology and hepatology (27) 27
hepatitis c virus (27) 27
young adult (27) 27
abridged index medicus (26) 26
double-blind method (26) 26
antiviral agents (25) 25
ribavirin (25) 25
viral load (25) 25
care and treatment (23) 23
ribavirin - administration & dosage (23) 23
ribavirin - adverse effects (23) 23
rna, viral - blood (23) 23
adolescent (21) 21
interferon-alpha - administration & dosage (21) 21
pharmacology. drug treatments (21) 21
gastroenterology. liver. pancreas. abdomen (20) 20
hepacivirus - drug effects (19) 19
hepatitis c - drug therapy (19) 19
interferon (19) 19
interferon-alpha - adverse effects (19) 19
polyethylene glycols - administration & dosage (19) 19
antibiotics. antiinfectious agents. antiparasitic agents (18) 18
hepatitis (18) 18
health aspects (17) 17
biological response modifiers (16) 16
dose-response relationship, drug (15) 15
medicine, general & internal (15) 15
polyethylene glycols - adverse effects (15) 15
general & internal medicine (14) 14
genetic aspects (14) 14
hiv (14) 14
hiv infections - complications (14) 14
recombinant proteins - therapeutic use (14) 14
drug therapy (13) 13
hepatitis c, chronic - complications (13) 13
microbiology (13) 13
pharmacology & pharmacy (13) 13
drug administration schedule (12) 12
genotype & phenotype (12) 12
liver. biliary tract. portal circulation. exocrine pancreas (12) 12
logistic models (12) 12
viral diseases of the lymphoid tissue and the blood. aids (12) 12
general aspects (11) 11
liver cirrhosis (11) 11
recombinant proteins - administration & dosage (11) 11
sofosbuvir (11) 11
uridine monophosphate - analogs & derivatives (11) 11
antiviral agents - pharmacokinetics (10) 10
hepacivirus - classification (10) 10
chronic hepatitis c (9) 9
clinical trials (9) 9
genetics (9) 9
hepatitis c, chronic - diagnosis (9) 9
hiv infections - drug therapy (9) 9
human immunodeficiency virus--hiv (9) 9
liver - pathology (9) 9
research (9) 9
uridine monophosphate - therapeutic use (9) 9
viral nonstructural proteins - antagonists & inhibitors (9) 9
virology (9) 9
aged, 80 and over (8) 8
analysis (8) 8
dosage and administration (8) 8
hepacivirus - isolation & purification (8) 8
hispanic americans (8) 8
infections (8) 8
mexico (8) 8
prospective studies (8) 8
antiviral agents - pharmacology (7) 7
biopsy (7) 7
diabetes mellitus, type 2 - genetics (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection
by Rodríguez-Torres, Maribel
Expert review of anti-infective therapy, ISSN 1478-7210, 12/2013, Volume 11, Issue 12, pp. 1269 - 1279
nucleotide analogue | direct-acting antiviral | chronic hepatitis C | Nucleotide analogue | Direct-acting antiviral | Chronic hepatitis C | Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Hepacivirus - drug effects | Recombinant Proteins - therapeutic use | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Biomarkers, Pharmacological | Interferon-alpha - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Treatment Outcome | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - therapeutic use | Drug Synergism | Uridine Monophosphate - analogs & derivatives | Hepacivirus - growth & development | Drug Therapy, Combination | Sofosbuvir | Uridine Monophosphate - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Treatment of HCV Infection by Targeting MicroRNA
by Janssen, Harry L.A and Reesink, Hendrik W and Lawitz, Eric J and Zeuzem, Stefan and Rodriguez-Torres, Maribel and Patel, Keyur and van der Meer, Adriaan J and Patick, Amy K and Chen, Alice and Zhou, Yi and Persson, Robert and King, Barney D and Kauppinen, Sakari and Levin, Arthur A and Hodges, Michael R
The New England journal of medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 18, pp. 1685 - 1694
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Viral hepatitis | Infectious diseases | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Hepacivirus - isolation & purification | Oligonucleotides - therapeutic use | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | MicroRNAs - metabolism | Oligonucleotides - adverse effects | RNA, Viral - blood | Binding Sites - genetics | Hepatitis C, Chronic - drug therapy | Dose-Response Relationship, Drug | Antiviral Agents - adverse effects | Injections, Subcutaneous | Adult | Female | Aged | Mutation | Hepatitis C, Chronic - genetics | MicroRNAs - chemistry | Antiviral agents | Care and treatment | MicroRNA | Research | Hepatitis C virus | Drug therapy | Health aspects | Liver diseases | Mortality | Liver | Body weight | Chronic infection | Antisense oligonucleotides | Genomes | Nucleic acids | Gene expression | Drug resistance | Patients | Hepatitis | miRNA | Phosphorothioate | Antisense DNA | Hepatitis C | Liver cirrhosis | Genotypes | Viral infections | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
by Lawitz, Eric, Prof and Sulkowski, Mark S, Prof and Ghalib, Reem, MD and Rodriguez-Torres, Maribel, MD and Younossi, Zobair M, Prof and Corregidor, Ana, MD and DeJesus, Edwin, MD and Pearlman, Brian, Prof and Rabinovitz, Mordechai, Prof and Gitlin, Norman, MD and Lim, Joseph K, MD and Pockros, Paul J, MD and Scott, John D, MD and Fevery, Bart, MSc and Lambrecht, Tom, MSc and Ouwerkerk-Mahadevan, Sivi, PhD and Callewaert, Katleen, MSc and Symonds, William T, PharmD and Picchio, Gaston, PhD and Lindsay, Karen L, MD and Beumont, Maria, MD and Jacobson, Ira M, Prof
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Simeprevir | Confidence Intervals | Follow-Up Studies | Humans | Middle Aged | Hepacivirus - genetics | Male | Reference Values | Polyethylene Glycols - therapeutic use | Dose-Response Relationship, Drug | Adult | Female | Drug Therapy, Combination | Liver Function Tests | Severity of Illness Index | Drug Administration Schedule | Risk Assessment | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Sulfonamides - therapeutic use | Heterocyclic Compounds, 3-Ring - therapeutic use | Uridine Monophosphate - analogs & derivatives | Hepatitis C, Chronic - genetics | Sofosbuvir | Hepatitis | Genotype & phenotype | Liver diseases | Biopsy | Infections | Drug therapy | Liver cirrhosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
by Nettles, Richard E and Gao, Min and Bifano, Marc and Chung, Ellen and Persson, Anna and Marbury, Thomas C and Goldwater, Ronald and DeMicco, Michael P and Rodriguez‐Torres, Maribel and Vutikullird, Apinya and Fuentes, Ernesto and Lawitz, Eric and Lopez‐Talavera, Juan Carlos and Grasela, Dennis M
Hepatology (Baltimore, Md.), ISSN 0270-9139, 12/2011, Volume 54, Issue 6, pp. 1956 - 1965
Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Biological and medical sciences | Medical sciences | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Hepacivirus - drug effects | Antiviral Agents - pharmacokinetics | Double-Blind Method | Humans | Middle Aged | Half-Life | Imidazoles - administration & dosage | Male | RNA, Viral - blood | Imidazoles - pharmacokinetics | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Viral Load | Adolescent | Adult | Female | Viral Nonstructural Proteins - antagonists & inhibitors | Hepatitis | Genotype & phenotype | Human immunodeficiency virus--HIV | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient
by Rodríguez-Torres, Maribel
Current opinion in infectious diseases, ISSN 0951-7375, 02/2013, Volume 26, Issue 1, pp. 50 - 57
direct-acting antiviral | drug-to-drug interactions | HIV/hepatitis C virus coinfection | chronic hepatitis C | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Hepacivirus - drug effects | Antiviral Agents - pharmacokinetics | Antiviral Agents - therapeutic use | Coinfection - drug therapy | Protease Inhibitors - pharmacokinetics | Humans | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Coinfection - virology | Drug Interactions | Anti-HIV Agents - pharmacokinetics | HIV Infections - complications | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
by Lawitz, Eric, Prof and Lalezari, Jay P, MD and Hassanein, Tarek, Prof and Kowdley, Kris V, Prof and Poordad, Fred F, Prof and Sheikh, Aasim M, MBBS and Afdhal, Nezam H, Prof and Bernstein, David E, Prof and DeJesus, Edwin, MD and Freilich, Bradley, MD and Nelson, David R, Prof and Dieterich, Douglas T, Prof and Jacobson, Ira M, Prof and Jensen, Donald, Prof and Abrams, Gary A, MD and Darling, Jama M, MD and Rodriguez-Torres, Maribel, MD and Reddy, K Rajender, Prof and Sulkowski, Mark S, Prof and Bzowej, Natalie H, MD and Hyland, Robert H, DPhil and Mo, Hongmei, PhD and Lin, Ming, PhD and Mader, Michael, MS and Hindes, Robert, MD and Albanis, Efsevia, MD and Symonds, William T, PharmD and Berrey, Michelle M, MD and Muir, Andrew, Prof
The Lancet infectious diseases, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Viral hepatitis | Infectious diseases | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Immunomodulators | Other diseases. Semiology | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes
by Mercader, Josep M and Liao, Rachel G and Bell, Avery D and Dymek, Zachary and Estrada, Karol and Tukiainen, Taru and Huerta-Chagoya, Alicia and Moreno-Macías, Hortensia and Jablonski, Kathleen A and Hanson, Robert L and Walford, Geoffrey A and Moran, Ignasi and Chen, Ling and Agarwala, Vineeta and Ordoñez-Sánchez, María Luisa and Rodríguez-Guillen, Rosario and Rodríguez-Torres, Maribel and Segura-Kato, Yayoi and García-Ortiz, Humberto and Centeno-Cruz, Federico and Barajas-Olmos, Francisco and Caulkins, Lizz and Puppala, Sobha and Fontanillas, Pierre and Williams, Amy L and Bonàs-Guarch, Sílvia and Hartl, Chris and Ripke, Stephan and Tooley, Katherine and Lane, Jacqueline and Zerrweck, Carlos and Martínez-Hernández, Angélica and Córdova, Emilio J and Mendoza-Caamal, Elvia and Contreras-Cubas, Cecilia and González-Villalpando, María E and Cruz-Bautista, Ivette and Muñoz-Hernández, Liliana and Gómez-Velasco, Donaji and Alvirde, Ulises and Henderson, Brian E and Wilkens, Lynne R and Le Marchand, Loic and Arellano-Campos, Olimpia and Riba, Laura and Harden, Maegan and Gabriel, Stacey and Abboud, Hanna E and Cortes, Maria L and Revilla-Monsalve, Cristina and Islas-Andrade, Sergio and Soberon, Xavier and Curran, Joanne E and Jenkinson, Christopher P and DeFronzo, Ralph A and Lehman, Donna M and Hanis, Craig L and Bell, Graeme I and Boehnke, Michael and Blangero, John and Duggirala, Ravindranath and Saxena, Richa and MacArthur, Daniel and Ferrer, Jorge and McCarroll, Steven A and Torrents, David and Knowler, William C and Baier, Leslie J and Burtt, Noel and González-Villalpando, Clicerio and Haiman, Christopher A and Aguilar-Salinas, Carlos A and Tusié-Luna, Teresa and Flannick, Jason and Jacobs, Suzanne B R and Orozco, Lorena and Altshuler, David and Florez, Jose C and Broad Genomics Platform and SIGMA T2D Genetics Consortium and Diabet Prevent Program Res Grp and T2D-GENES Consortium and Diabetes Prevention Program Research Group
Diabetes (New York, N.Y.), ISSN 0012-1797, 11/2017, Volume 66, Issue 11, pp. 2903 - 2914
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Cell Line | RNA Splice Sites - genetics | Diabetes Mellitus, Type 2 - genetics | Humans | Liver | Gene Expression Regulation - physiology | European Continental Ancestry Group | Genotype | Insulin-Like Growth Factor II - metabolism | Genetic Variation | Stem Cells | Mexican Americans - genetics | Insulin-Like Growth Factor II - genetics | Protein Isoforms | Mexico | Adipose Tissue | Health care | Reproductive health | Medical research | Adipose tissue | Splicing | Exons | Diabetes mellitus | Genomes | Genetic diversity | Population genetics | Genetic variance | Gene frequency | Alleles | Hemoglobin | Diabetes | Insulin-like growth factor II | Index Medicus | Abridged Index Medicus | Metabolomics | Genetics | 0409 | Proteomics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Latinos and Chronic Hepatitis C: A Singular Population
by Rodríguez–Torres, Maribel
Clinical gastroenterology and hepatology, ISSN 1542-3565, 2008, Volume 6, Issue 5, pp. 484 - 490
Gastroenterology and Hepatology | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Liver Function Tests | Severity of Illness Index | United States - epidemiology | Risk Assessment | Antiviral Agents - therapeutic use | Humans | Interferon-alpha - therapeutic use | Hispanic Americans - statistics & numerical data | Male | Hepatitis C, Chronic - ethnology | Recombinant Proteins | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Incidence | Drug Resistance, Viral - ethnology | Survival Analysis | Female | Development and progression | Insulin resistance | Hepatitis C | Biological response modifiers | Hispanic Americans | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Contribution of common genetic variation to the risk of type 2 diabetes in the Mexican Mestizo population
by Gamboa-Meléndez, Marco Alberto and Huerta-Chagoya, Alicia and Moreno-Macías, Hortensia and Vázquez-Cárdenas, Paola and Ordóñez-Sánchez, María Luisa and Rodríguez-Guillén, Rosario and Riba, Laura and Rodríguez-Torres, Maribel and Guerra-García, María Teresa and Guillén-Pineda, Luz Elizabeth and Choudhry, Shweta and Del Bosque-Plata, Laura and Canizales-Quinteros, Samuel and Pérez-Ortiz, Gustavo and Escobedo-Aguirre, Fernando and Parra, Adalberto and Lerman-Garber, Israel and Aguilar-Salinas, Carlos Alberto and Tusié-Luna, María Teresa
Diabetes (New York, N.Y.), ISSN 0012-1797, 12/2012, Volume 61, Issue 12, pp. 3314 - 3321
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Diabetes. Impaired glucose tolerance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | RNA-Binding Proteins - genetics | Calcium-Calmodulin-Dependent Protein Kinase Type 1 - genetics | Genetic Predisposition to Disease - genetics | Genome-Wide Association Study | KCNQ1 Potassium Channel - genetics | Transcription Factor 7-Like 2 Protein - genetics | Zinc Transporter 8 | Diabetes Mellitus, Type 2 - genetics | Humans | Middle Aged | Genotype | Male | Transcription Factors - genetics | Homeodomain Proteins - genetics | Cyclin-Dependent Kinase 5 - genetics | Cyclin-Dependent Kinase Inhibitor p15 - genetics | tRNA Methyltransferases | Polymorphism, Single Nucleotide - genetics | Cation Transport Proteins - genetics | Female | Mexico | Type 2 diabetes | Racially mixed people | Genetic variation | Mexicans | Genetic aspects | Health aspects | Risk factors | Index Medicus | Abridged Index Medicus | Metabolomics | Genetics | Genomes | Proteomics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights